Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine

Vaccine

Volumn 30, Issue 2, 2012, Pages 155-160

  Claus, Heike ^a   Jördens, Markus S ^a,b   Kriz, Pavla ^c   Musilek, Martin ^c   Jarva, Hanna ^b   Pawlik, Marie Christin ^a   Meri, Seppo ^b   Vogel, Ulrich ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Neisseria meningitidis; Typing; Vaccine

Indexed keywords

ANTIGEN; BINDING PROTEIN; FACTOR H BINDING PROTEIN; HEPARIN BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL HEPARIN BINDING ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; CROSS REACTION; GENE EXPRESSION; IMMUNIZATION; IN VITRO STUDY; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADHESINS, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; GENE EXPRESSION; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS;

EID: 84355161416     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.050     Document Type: Article

References (52)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
2. Caugant D.A., Tzanakaki G., Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007, 31(1):52-63.
3. Yazdankhah S.P., Kriz P., Tzanakaki G., Kremastinou J., Kalmusova J., Musilek M., et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004, 42(11):5146-5153.
4. Claus H., Maiden M.C., Wilson D.J., McCarthy N.D., Jolley K.A., Urwin R., et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005, 191(8):1263-1271.
5. Claus H., Maiden M.C., Maag R., Frosch M., Vogel U. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 2002, 148(Pt 6):1813-1819.
6. Vogel U., Claus H., von Muller L., Bunjes D., Elias J., Frosch M. Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J Clin Microbiol 2004, 42(7):2898-2901.
7. Findlow H., Vogel U., Mueller J.E., Curry A., Njanpop-Lafourcade B.M., Claus H., et al. Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis 2007, 195(7):1071-1077.
8. Hoang L.M., Thomas E., Tyler S., Pollard A.J., Stephens G., Gustafson L., et al. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 2005, 40(5):e38-e42.
9. Elias J., Harmsen D., Claus H., Hellenbrand W., Frosch M., Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 2006, 12(11):1689-1695.
10. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
11. Trotter C.L., Gay N.J., Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, 134(3):556-566.
12. Oliver K.J., Reddin K.M., Bracegirdle P., Hudson M.J., Borrow R., Feavers I.M., et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002, 70(7):3621-3626.
13. Guzzetta G., Manfredi P., Gasparini R., Panatto D., Edmunds W.J. On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity. Vaccine 2009, 27(25-26):3429-3434.
14. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362(16):1511-1520.
15. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(29):10834-10839.
16. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
17. Comanducci M., Bambini S., Brunelli B., du-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195(11):1445-1454.
18. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107(8):3770-3775.
19. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
20. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72(7):4217-4223.
21. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
22. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27(21):2794-2803.
23. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107(45):19490-19495.
24. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
25. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29(11):e71-e79.
26. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95(6):3140-3145.
27. Kurzai O., Schmitt C., Claus H., Vogel U., Frosch M., Kolb-Maurer A. Carbohydrate composition of meningococcal lipopolysaccharide modulates the interaction of Neisseria meningitidis with human dendritic cells. Cell Microbiol 2005, 7(9):1319-1334.
28. Vogel U., Morelli G., Zurth K., Claus H., Kriener E., Achtman M., et al. Necessity of molecular techniques to distinguish between Neisseria meningitidis strains isolated from patients with meningococcal disease and from their healthy contacts. J Clin Microbiol 1998, 36(9):2465-2470.
29. Thompson E.A., Feavers I.M., Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149(Pt 7):1849-1858.
30. Urwin R., Russell J.E., Thompson E.A., Holmes E.C., Feavers I.M., Maiden M.C. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004, 72(10):5955-5962.
31. Brehony C., Wilson D.J., Maiden M.C. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009, 155(Pt 12):4155-4169.
32. Jolley K.A., Maiden M.C., BIGSdb Scalable analysis of bacterial genome variation at the population level. BMC Bioinform 2010, 11:595.
33. Huson D.H. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics 1998, 14(1):68-73.
34. Pizza M., Donnelly J., Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine 2008, 26(SUPPL. 8):I46-I48.
35. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
36. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
37. Vogel U., Hammerschmidt S., Frosch M. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med Microbiol Immunol 1996, 185(2):81-87.
38. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51(9):717-722.
39. Uria M.J., Zhang Q., Li Y., Chan A., Exley R.M., Gollan B., et al. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 2008, 205(6):1423-1434.
40. Kugelberg E., Gollan B., Farrance C., Bratcher H., Lucidarme J., Ibarz-Pavon A.B., et al. The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease. PLoS ONE 2010, 5(2):e9413.
41. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):279-289.
42. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009, 47(11):3577-3585.
43. Schoen C., Blom J., Claus H., Schramm-Gluck A., Brandt P., Muller T., et al. Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci U S A 2008, 105(9):3473-3478.
44. Vipond C., Suker J., Jones C., Tang C., Feavers I.M., Wheeler J.X. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 2006, 6(11):3400-3413.
45. Elias J., Vogel U. IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone. J Clin Microbiol 2007, 45(1):159-167.
46. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004, 190(8):1488-1497.
47. Meri S., Pangburn M.K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A 1990, 87(10):3982-3986.
48. Pizza M., Scarlato V., Masignani V., Giuliani M-M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
49. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, 28(31):5023-5030.
50. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
51. Brunelli B., Del Tordello E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011, 29:1072-1081.
52. Dolan-Livengood J.M., Miller Y.K., Martin L.E., Urwin R., Stephens D.S. Genetic basis for nongroupable Neisseria meningitidis. J Infect Dis 2003, 187(10):1616-1628.